Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Ruden E, Reardon DA, Coan AD, Herndon JE 2nd, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW.

J Clin Oncol. 2011 Jul 20;29(21):2918-23. doi: 10.1200/JCO.2011.34.9852. Epub 2011 Jun 20.

2.

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.

Peters KB, West MJ, Hornsby WE, Waner E, Coan AD, McSherry F, Herndon JE 2nd, Friedman HS, Desjardins A, Jones LW.

J Neurooncol. 2014 Dec;120(3):499-506. doi: 10.1007/s11060-014-1574-3. Epub 2014 Aug 13.

3.

Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.

Jones LW, Hornsby WE, Goetzinger A, Forbes LM, Sherrard EL, Quist M, Lane AT, West M, Eves ND, Gradison M, Coan A, Herndon JE, Abernethy AP.

Lung Cancer. 2012 May;76(2):248-52. doi: 10.1016/j.lungcan.2011.10.009. Epub 2011 Nov 22.

4.

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.

Jones LW, Cohen RR, Mabe SK, West MJ, Desjardins A, Vredenburgh JJ, Friedman AH, Reardon DA, Waner E, Friedman HS.

J Neurooncol. 2009 Aug;94(1):79-85. doi: 10.1007/s11060-009-9803-x. Epub 2009 Feb 11.

PMID:
19212703
5.

Indicators of functional status for primary malignant brain tumour patients.

Bussière M, Hopman W, Day A, Pombo AP, Neves T, Espinosa F.

Can J Neurol Sci. 2005 Feb;32(1):50-6.

PMID:
15825546
6.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.

7.

Long-term prognostic assessment of 185 newly diagnosed gliomas: Grade III glioma showed prognosis comparable to that of Grade II glioma.

Shinohara C, Muragaki Y, Maruyama T, Shimizu S, Tanaka M, Kubota Y, Oikawa M, Nakamura R, Iseki H, Kubo O, Takakura K, Hori T.

Jpn J Clin Oncol. 2008 Nov;38(11):730-3. doi: 10.1093/jjco/hyn099. Epub 2008 Sep 26.

9.

Temozolomide in the treatment of recurrent malignant glioma.

Chang SM, Theodosopoulos P, Lamborn K, Malec M, Rabbitt J, Page M, Prados MD.

Cancer. 2004 Feb 1;100(3):605-11.

10.

Treating high grade gliomas in the elderly: the end of ageism?

Mukerji N, Rodrigues D, Hendry G, Dunlop PR, Warburton F, Kane PJ.

J Neurooncol. 2008 Feb;86(3):329-36. Epub 2007 Nov 17.

PMID:
18026688
11.

Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy.

Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, Brada M.

Eur J Cancer. 1994;30A(12):1809-15.

PMID:
7880611
12.

Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.

Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H.

J Clin Oncol. 1997 Sep;15(9):3129-40.

PMID:
9294476
13.

Clinical prognostic factors in patients with malignant glioma treated with combined modality approach.

Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J, Nikolic N.

Am J Clin Oncol. 2004 Apr;27(2):195-204.

PMID:
15057161
14.

Parameters assessing neurological status in malignant glioma patients: prognostic value for survival and relapse-free time.

Martinez R, Volter C, Behr R.

Br J Neurosurg. 2008 Aug;22(4):557-62. doi: 10.1080/02688690802166424.

PMID:
18686059
15.

Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.

Murray KJ, Nelson DF, Scott C, Fischbach AJ, Porter A, Farnan N, Curran WJ Jr.

Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):453-9.

PMID:
7852106
16.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

17.

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z.

Neuro Oncol. 2003 Apr;5(2):79-88.

18.

Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.

Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L.

Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):39-51. Epub 2004 Aug 10.

PMID:
15309329
19.

Verbally administered Barthel Index as functional assessment in brain tumour patients.

Brazil L, Thomas R, Laing R, Hines F, Guerrero D, Ashley S, Brada M.

J Neurooncol. 1997 Sep;34(2):187-92.

PMID:
9210067
20.

A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival.

Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC.

Neurosurgery. 2005 Sep;57(3):495-504; discussion 495-504.

PMID:
16145528
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk